journal article·2025-06-13Open access

In Vitro Evaluation of Flame-Made Calcium Phosphate Nanoparticles for Antigen Delivery and Immunostimulation

Anshika Maheshwari, Rebecca Dookie, Meztlli O. Gaytán, Birgitta Henriques-Normark, Georgios A. Sotiriou

ACS Applied Nano Materials· Volume 8· Issue 23

Abstract

High Resolution Image Download MS PowerPoint Slide The use of nanoparticles in vaccine formulations has become increasingly prevalent, with the rise of subunit vaccines. However, the production of nanoparticles is often not scalable, presenting a significant challenge for large-scale vaccine manufacturing. Additionally, these nanoparticle delivery systems often require additional immunopotentiators to elicit a robust immune response, further complicating vaccine formulation. In this study, we explore the potential of flame-synthesized calcium phosphate (CaP) nanoparticles, produced via flame spray pyrolysis (FSP) (a highly reproducible and scalable method), as vaccine adjuvants capable of both antigen delivery and immunostimulation. We produced three different CaP nanoparticles with controlled crystallinity and size to screen for their immunostimulatory properties and evaluated their capacity to load and protect the model antigen ovalbumin (OVA) from enzymatic degradation. Our results show that all three CaP nanoparticles significantly enhance antigen internalization and processing by bone marrow-derived dendritic cells (BMDCs), critical for effective T cell activation. OVA conjugated with amorphous CaP nanoparticles outperformed crystalline CaP in increasing the expression of costimulatory markers CD86 and CD80 on BMDCs, as well as enhancing IL-6 production, indicating their potential as effective immunopotentiators. This dual functionality, in addition to the facile synthesis process, could simplify vaccine formulations by obviating the need for separate immunostimulatory agents. This work lays the foundation for further research to establish the flame-made CaP nanoparticle effectiveness and safety as adjuvants in vivo .
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: RNA Interference and Gene Delivery · Nanoplatforms for cancer theranostics · Advanced Drug Delivery Systems

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Microbiology, Tumor and Cell Biology

Karolinska Institutet

Clinical Microbiology

Karolinska University Hospital

Department of Chemistry, Science for Life Laboratory

Stockholm University

Funding

Vetenskapsr?det · Torsten S?derbergs Stiftelse · Karolinska Institutet · H2020 European Research Council · Stiftelsen f?r Strategisk Forskning

References (62)

Show source-provided references
1. 10.1097/MOP.000000000000086810.1097/MOP.0000000000000868 ↗
2. 10.1111/j.0818-9641.2004.01272.x10.1111/j.0818-9641.2004.01272.x ↗
3. 10.1016/0264-410X(93)90190-910.1016/0264-410X(93)90190-9 ↗
4. Mohan T. · Indian J. Med. Res. · 2013 · 138 · 779
5. 10.3390/vaccines1111170410.3390/vaccines11111704 ↗
6. 10.1080/14760584.2017.135573310.1080/14760584.2017.1355733 ↗
7. 10.1016/j.coi.2017.06.00510.1016/j.coi.2017.06.005 ↗
8. 10.1016/j.immuni.2007.11.00310.1016/j.immuni.2007.11.003 ↗
9. 10.7774/cevr.2015.4.1.2310.7774/cevr.2015.4.1.23 ↗
10. Waccnes, A.; Relyveld, E. H.; Paris, F. Calcium Phosphate Gel for Adsorbing Vaccines. U.S. Patent US4016252A, 1975.
11. Relyveld E. H. · Dev. Biol. Stand. · 1986 · 65 · 131
12. 10.1128/CDLI.7.6.899-903.200010.1128/CDLI.7.6.899-903.2000 ↗
13. 10.1080/14760584.2017.124448410.1080/14760584.2017.1244484 ↗
14. 10.1002/1521-3773(20020902)41:17<3130::AID-ANIE3130>3.0.CO;2-110.1002/1521-3773(20020902)41:17<3130::AID-ANIE3130>3.0.CO;2-1 ↗
15. 10.1016/j.vaccine.2019.04.05510.1016/j.vaccine.2019.04.055 ↗
16. 10.3389/fmats.2021.78837310.3389/fmats.2021.788373 ↗
17. 10.1016/j.biomaterials.2014.04.01010.1016/j.biomaterials.2014.04.010 ↗
18. 10.1039/C8CS00028J10.1039/C8CS00028J ↗
19. 10.1128/CDLI.9.5.1021-1024.200210.1128/CDLI.9.5.1021-1024.2002 ↗
20. 10.1166/jbn.2013.154510.1166/jbn.2013.1545 ↗
21. 10.1021/acsomega.0c0179210.1021/acsomega.0c01792 ↗
22. 10.1038/s41598-017-03086-010.1038/s41598-017-03086-0 ↗
23. 10.3390/pharmaceutics1412255410.3390/pharmaceutics14122554 ↗
24. 10.1016/j.colsurfb.2015.05.01410.1016/j.colsurfb.2015.05.014 ↗
25. 10.1016/j.actbio.2013.04.01210.1016/j.actbio.2013.04.012 ↗
26. 10.1186/s12951-024-02311-z10.1186/s12951-024-02311-z ↗
27. 10.1038/s43246-024-00475-710.1038/s43246-024-00475-7 ↗
28. 10.3390/pharmaceutics1511262310.3390/pharmaceutics15112623 ↗
29. 10.1007/s13346-021-01024-210.1007/s13346-021-01024-2 ↗
30. 10.1039/c0nr00017e10.1039/c0nr00017e ↗
31. 10.1007/s11051-015-2901-010.1007/s11051-015-2901-0 ↗
32. 10.1016/j.bios.2020.11273210.1016/j.bios.2020.112732 ↗
33. 10.3390/molecules2507174710.3390/molecules25071747 ↗
34. 10.1016/S0021-8502(01)00159-810.1016/S0021-8502(01)00159-8 ↗
35. 10.1088/0957-4484/16/7/03910.1088/0957-4484/16/7/039 ↗
36. 10.1016/S0009-2509(03)00022-810.1016/S0009-2509(03)00022-8 ↗
37. 10.1002/aic.1688510.1002/aic.16885 ↗
38. 10.1016/j.bios.2019.03.01210.1016/j.bios.2019.03.012 ↗
39. 10.1021/cm048776c10.1021/cm048776c ↗
40. 10.1021/acsnano.7b0551810.1021/acsnano.7b05518 ↗
41. 10.1021/acsnano.4c0468510.1021/acsnano.4c04685 ↗
42. 10.1039/B910885H10.1039/B910885H ↗
43. 10.1016/j.colsurfb.2015.12.00410.1016/j.colsurfb.2015.12.004 ↗
44. 10.3389/fcimb.2021.78763510.3389/fcimb.2021.787635 ↗
45. 10.1016/j.cej.2021.12974610.1016/j.cej.2021.129746 ↗
46. 10.1038/s41392-023-01557-710.1038/s41392-023-01557-7 ↗
47. 10.1146/annurev.immunol.18.1.76710.1146/annurev.immunol.18.1.767 ↗
48. 10.1146/annurev-immunol-061020-05370710.1146/annurev-immunol-061020-053707 ↗
49. 10.1016/j.drudis.2009.02.00910.1016/j.drudis.2009.02.009 ↗
50. 10.2147/IJN.S24246310.2147/IJN.S242463 ↗
51. 10.1038/nri308410.1038/nri3084 ↗
52. 10.4049/jimmunol.165.1.4910.4049/jimmunol.165.1.49 ↗
53. 10.1073/pnas.96.26.1505610.1073/pnas.96.26.15056 ↗
54. 10.3389/fimmu.2020.62193110.3389/fimmu.2020.621931 ↗
55. 10.1016/j.imlet.2024.10687010.1016/j.imlet.2024.106870 ↗
56. 10.1126/sciadv.aaz446210.1126/sciadv.aaz4462 ↗
57. 10.1002/adhm.20210123910.1002/adhm.202101239 ↗
58. 10.1021/acsapm.3c0054810.1021/acsapm.3c00548 ↗
59. 10.1007/s12274-023-6213-x10.1007/s12274-023-6213-x ↗
60. 10.1039/D3NA00867C10.1039/D3NA00867C ↗
61. 10.3390/cancers1518462610.3390/cancers15184626 ↗
62. 10.1016/j.cej.2024.14861110.1016/j.cej.2024.148611 ↗